Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Stage/Subtype:  recurrent adult brain tumor
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 103 for your search:
Start Over
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: OT-15-001, NCI-2016-01159, NCT02796261
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, CR00002456, 2868, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Everolimus and Sorafenib Tosylate in Treating Patients with Recurrent High-Grade Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0011, NCI-2015-02100, P152430, BTTC09-01, NCT01434602
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: HCI55264, NCI-2012-01118, 55264, NCT01580969
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTRC# 12-02, NCI-2014-00900, 193831, 20141749, 1-874640-1, HSC20140450X, NCI-2014-00412, 1149367, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Study of Marizomib With Bevacizumab in Subjects With WHO Grade IV Malignant Glioma Followed by a Trial of Single-Agent Marizomib
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MRZ-108, NCI-2015-00711, NCT02330562
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15702, NCI-2015-02229, H9H-MC-JBEF, NCT02423343
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-209, NCI-2016-00105, NCT02586857
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients with Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0899, NCI-2016-00183, NCT02661282
iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00000922, NCI-2013-00781, CR00023930, MR00041590, CR00018679, eIRB #922, CR00021317, ONC-02019-L, CR00022743, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Temozolomide and Lapatinib Ditosylate in Treating Patients with Recurrent Low-Grade Ependymoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-N005, NCI-2012-02131, CERN 08-02, P152451, NCT00826241
Aminolevulinic Acid in Measuring Brain Tumors in Patients With High Grade Glioma Undergoing Surgery
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 to 72
Trial IDs: 10101, NCI-2011-01264, NCT01116661
Proton Beam Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma or Hemangiopericytoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 24309, NCI-2010-01084, NCT01117844
Nilotinib in Treating Patients with Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCI-2012-02871, NCT01140568
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0009, NCI-2011-01283, CERN 09-02, P152432, NCT01295944
Start Over